Media headlines about MiMedx Group (NASDAQ:MDXG) have been trending somewhat positive recently, Accern reports. The research firm ranks the sentiment of media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. MiMedx Group earned a news sentiment score of 0.12 on Accern’s scale. Accern also assigned headlines about the medical equipment provider an impact score of 45.6319945120254 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Here are some of the headlines that may have impacted Accern Sentiment Analysis’s rankings:
- MiMedx Announces Release Date for 2017 Third Quarter Results (finance.yahoo.com)
- MiMedx Group (MDXG) Says it Added New Materials to Its Website Exposing Misinformation Disseminated Through Short Attack (streetinsider.com)
- MiMedx Group (MDXG) Says it Added New Materials to Its Website Exposing Misinformation Disseminated Through … – StreetInsider.com (streetinsider.com)
- MiMedx Group, Inc (MDXG) Short Interest Update (americanbankingnews.com)
- Technical Reports on Medical Equipment Equities — Nxstage Medical, MiMedx, Hologic, and Wright Medical (bizjournals.com)
Several equities research analysts have weighed in on MDXG shares. Piper Jaffray Companies reissued a “buy” rating and set a $18.00 price objective on shares of MiMedx Group in a research note on Sunday, August 20th. Needham & Company LLC upped their target price on MiMedx Group from $20.00 to $21.00 and gave the company a “strong-buy” rating in a research note on Tuesday, September 5th. Zacks Investment Research cut MiMedx Group from a “hold” rating to a “sell” rating in a research note on Tuesday, October 10th. Lake Street Capital upped their target price on MiMedx Group from $16.00 to $18.00 and gave the company a “buy” rating in a research note on Friday, July 28th. Finally, BidaskClub raised MiMedx Group from a “hold” rating to a “buy” rating in a research note on Saturday, June 24th. Three equities research analysts have rated the stock with a sell rating, one has given a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $14.83.
MiMedx Group (MDXG) traded up 2.29% on Tuesday, hitting $13.82. The stock had a trading volume of 2,571,337 shares. The stock has a market cap of $1.48 billion, a PE ratio of 72.74 and a beta of 0.92. MiMedx Group has a 12 month low of $7.64 and a 12 month high of $17.47. The firm’s 50 day moving average price is $13.56 and its 200-day moving average price is $13.90.
MiMedx Group (NASDAQ:MDXG) last announced its quarterly earnings results on Wednesday, July 26th. The medical equipment provider reported $0.07 earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of $0.07. The business had revenue of $76.40 million during the quarter, compared to the consensus estimate of $74.22 million. MiMedx Group had a net margin of 7.48% and a return on equity of 15.95%. The business’s revenue was up 33.3% compared to the same quarter last year. During the same quarter last year, the firm earned $0.05 EPS. On average, analysts forecast that MiMedx Group will post $0.31 EPS for the current year.
MiMedx Group announced that its Board of Directors has initiated a share buyback program on Wednesday, July 26th that permits the company to buyback $14.00 million in shares. This buyback authorization permits the medical equipment provider to reacquire up to 0.9% of its stock through open market purchases. Stock buyback programs are often a sign that the company’s board of directors believes its shares are undervalued.
WARNING: This article was first published by Community Financial News and is the property of of Community Financial News. If you are accessing this article on another website, it was illegally copied and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this article can be viewed at https://www.com-unik.info/2017/10/17/mimedx-group-mdxg-receiving-somewhat-favorable-press-coverage-accern-reports.html.
MiMedx Group Company Profile
MiMedx Group, Inc is an integrated developer, processor and marketer of regenerative biomaterial products and bioimplants human placental tissue, skin and bone. The Company’s Regenerative Biomaterials segment includes the design, manufacture, and marketing of products and tissue processing services for the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental market categories.
What are top analysts saying about MiMedx Group Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for MiMedx Group Inc and related companies.